APA (7th ed.) Citation

Ellis, A. K., Murrieta-Aguttes, M., Furey, S., & Carlsten, C. (2020). Phase 3, single-center, sequential and parallel-group, double-blind, randomized study evaluating the efficacy and safety of Fexofenadine Hydrochloride 180 mg (Allegra®/Telfast®) versus placebo in subjects suffering from seasonal Allergic Rhinitis with symptoms aggravated in presence of pollutants. The World Allergy Organization journal, 13(8), 100267. https://doi.org/10.1016/j.waojou.2020.100267

Chicago Style (17th ed.) Citation

Ellis, Anne K., Margarita Murrieta-Aguttes, Sandy Furey, and Christopher Carlsten. "Phase 3, Single-center, Sequential and Parallel-group, Double-blind, Randomized Study Evaluating the Efficacy and Safety of Fexofenadine Hydrochloride 180 Mg (Allegra®/Telfast®) Versus Placebo in Subjects Suffering from Seasonal Allergic Rhinitis with Symptoms Aggravated in Presence of Pollutants." The World Allergy Organization Journal 13, no. 8 (2020): 100267. https://doi.org/10.1016/j.waojou.2020.100267.

MLA (9th ed.) Citation

Ellis, Anne K., et al. "Phase 3, Single-center, Sequential and Parallel-group, Double-blind, Randomized Study Evaluating the Efficacy and Safety of Fexofenadine Hydrochloride 180 Mg (Allegra®/Telfast®) Versus Placebo in Subjects Suffering from Seasonal Allergic Rhinitis with Symptoms Aggravated in Presence of Pollutants." The World Allergy Organization Journal, vol. 13, no. 8, 2020, p. 100267, https://doi.org/10.1016/j.waojou.2020.100267.